Cipla Secures Rights to Investigational HER2 Cancer Therapy TQB2102 Across India and Emerging Markets

Indian pharmaceutical major Cipla Limited has secured exclusive rights to develop and commercialise the investigational cancer therapy Rolditamig Deuderuxtecan, or TQB2102, across India, South Africa and five other emerging markets, strengthening the company’s presence in advanced oncology and targeted cancer treatment.

The agreement, announced on August 31, 2026, has been signed with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a subsidiary of Sino Biopharmaceutical Limited. Under the exclusive licence and supply arrangement, Cipla will take responsibility for local clinical development, regulatory submissions and eventual commercialisation of TQB2102 in the licensed territories, while Chia Tai Tianqing will continue to manufacture and supply the investigational medicine.

The partnership gives Cipla access to one of Sino Biopharmaceutical’s more advanced oncology assets at a time when antibody-drug conjugates are emerging as an important new generation of targeted cancer medicines. The companies intend to use Cipla’s regulatory, medical, market-access and commercial network to accelerate development of the therapy in the licensed countries, although any future availability will depend on successful clinical trials and regulatory approval.

TQB2102 Targets HER2-Expressing Cancer Cells

Rolditamig Deuderuxtecan is a bispecific HER2-targeted antibody-drug conjugate, commonly abbreviated as an ADC. Rather than functioning like conventional chemotherapy that circulates throughout the body and affects rapidly dividing cells more broadly, an ADC is designed to use an antibody to recognise a molecular target found on cancer cells and deliver a potent anti-cancer payload more selectively.

TQB2102 targets human epidermal growth factor receptor 2, or HER2, a protein that can be present at elevated or varying levels on the surface of several types of cancer cells. HER2 has long been an important therapeutic target in breast cancer, but newer generations of drugs are increasingly being investigated across tumours with lower levels of HER2 expression as well as cancers affecting other organs.

What distinguishes TQB2102 from conventional HER2-targeting antibodies is its bispecific design. The antibody component can bind simultaneously to two different regions of the HER2 protein, known as extracellular domains II and IV. These correspond to regions targeted individually by established HER2 therapies such as pertuzumab and trastuzumab.

By recognising two non-overlapping HER2 sites, the developers are attempting to improve binding to tumour cells and enhance delivery of the drug payload. Whether this translates into superior outcomes compared with existing therapies must ultimately be established through larger controlled clinical trials.

A Potent Anti-Cancer Payload Delivered to the Tumour

The antibody component of TQB2102 is connected through an enzyme-cleavable linker to a topoisomerase I inhibitor, a potent class of anti-cancer compound that interferes with the mechanisms cancer cells use to replicate their DNA.

The concept behind an antibody-drug conjugate is therefore sometimes compared with a targeted delivery system. The antibody seeks out cells carrying the relevant molecular marker, after which the attached cytotoxic payload can be released in or around the tumour cell.

This strategy has transformed parts of modern oncology because it can combine the targeting characteristics of biologic medicines with the cell-killing potency of chemotherapy. However, ADCs can still produce serious adverse effects, and their safety depends on factors including the antibody, linker, payload, dose and characteristics of individual patients.

TQB2102 remains under clinical investigation, and the benefits and risks observed in early studies still require confirmation in larger trials before regulators can determine whether it should be approved.

Encouraging Early Results in HER2-Low Breast Cancer

Particular interest in TQB2102 has arisen from its early clinical activity in patients with HER2-low recurrent or metastatic breast cancer, a population in which cancer cells carry detectable HER2 but do not express the protein at the high levels traditionally associated with HER2-positive disease.

Results presented at the 2025 American Society of Clinical Oncology Annual Meeting included data from a Phase 1b study involving 73 patients with heavily pretreated HER2-low recurrent or metastatic breast cancer. Patients received either 6 mg/kg or 7.5 mg/kg of TQB2102 intravenously every three weeks.

Across the two dosage groups, researchers reported an objective response rate of 53.4%, meaning that just over half of the patients had a predefined reduction in measurable tumour burden during the study period. The reported response rate was 58.3% at the 7.5 mg/kg dose and 48.7% at the 6 mg/kg dose. The disease-control rate across the cohort was reported at 86.3%.

These findings were encouraging because the patients had already received substantial previous treatment, with a median of four prior lines of therapy in the metastatic setting. Nevertheless, the results came from an early-stage study without the scale and comparative design required to establish whether TQB2102 provides a meaningful advantage over currently available standard therapies.

Based partly on these findings, researchers selected 7.5 mg/kg every three weeks as the recommended Phase III dose for patients with HER2-low recurrent or metastatic breast cancer.

Phase III Development Already Underway

TQB2102 has subsequently progressed into Phase III clinical development in China, an important milestone because Phase III studies are generally designed to compare an investigational therapy directly with established treatment and provide much of the evidence regulators use when considering marketing approval.

The ongoing Phase III study in HER2-low recurrent or metastatic breast cancer is evaluating TQB2102 against investigator-selected chemotherapy. The trial is registered as NCT06561607.

Sino Biopharmaceutical has also identified a considerably wider development programme around the molecule. Potential areas being investigated include HER2-positive breast cancer and other tumours involving HER2 mutation, amplification or expression, including certain lung, gastrointestinal and biliary cancers.

The breadth of the programme is significant because HER2 is not exclusively a breast-cancer target. Molecular testing has increasingly revealed HER2-related abnormalities in several solid tumours, allowing developers to investigate medicines according to the biological characteristics of a cancer rather than only the organ in which it originated.

Early Trials Have Examined Several Solid Tumours

An earlier first-in-human Phase I programme evaluated TQB2102 in patients with several advanced solid cancers. Data presented at ASCO included 181 participants across 12 centres, with metastatic breast cancer, colorectal cancer and gastric cancer among the largest disease groups represented.

Among response-evaluable patients treated across the study, investigators reported an overall objective response rate of 41.2%, although results varied substantially according to tumour type, HER2 expression and dose. Early signals of activity were reported in HER2-positive and HER2-low metastatic breast cancer as well as selected gastric and colorectal cancers.

The results remain preliminary. Early-phase oncology studies are primarily designed to investigate safety, dosing and initial evidence of activity, and response rates observed in relatively small or selected patient groups cannot by themselves establish how a medicine will perform in routine clinical practice.

The larger Phase III trials will therefore be crucial in determining whether the encouraging early activity can be reproduced against established treatment options and whether the treatment provides an acceptable balance between clinical benefit and toxicity.

Safety Will Remain a Major Part of Development

Like other potent antibody-drug conjugates, TQB2102 has produced treatment-related adverse events during clinical testing. In the Phase 1b HER2-low breast-cancer study, commonly reported effects included decreases in white blood cells and neutrophils, anaemia, nausea and vomiting. Grade 3 or higher treatment-related adverse events were reported in 41.1% of patients in that cohort.

In the wider first-in-human study, investigators also monitored patients closely for interstitial lung disease, a potentially serious complication associated with some HER2-directed antibody-drug conjugates. One Grade 2 case was reported in the broader early-phase dataset available at the time of the ASCO presentation.

These findings underline why TQB2102 should currently be regarded as a promising investigational therapy rather than an established treatment. Larger studies with longer follow-up will be needed to characterise both its efficacy and safety more completely.

Cipla Will Lead Development in India

Under the new agreement, Cipla will be responsible for the local clinical-development programme, regulatory activities and commercialisation required to potentially introduce TQB2102 in India and the other licensed markets. Chia Tai Tianqing will retain responsibility for manufacturing and supplying the product.

This division of responsibilities allows Sino Biopharmaceutical to combine its drug-development and manufacturing capabilities with Cipla’s established presence in markets where regulatory requirements, healthcare systems, pricing structures and patient-access mechanisms can differ substantially.

For Cipla, the agreement expands its oncology pipeline beyond conventional generic and branded medicines and gives the company a stake in the development of a comparatively sophisticated biological cancer therapy.

Cipla Managing Director and Global Chief Executive Officer Achin Gupta described the agreement as part of the company’s effort to expand access to therapies addressing significant unmet medical needs, particularly breast cancer. Sino Biopharmaceutical similarly said Cipla’s scale and local market expertise made it a suitable partner for expanding the geographic reach of the programme.

Growing Importance of HER2-Low Breast Cancer

One reason TQB2102 has attracted attention is the changing scientific understanding of HER2 expression in breast cancer. Historically, breast tumours were commonly divided into HER2-positive and HER2-negative categories, with HER2-targeted drugs concentrated largely in patients whose tumours strongly overexpressed the protein.

More sensitive biological classification has subsequently created the concept of HER2-low breast cancer, covering tumours that have lower but still detectable quantities of HER2. The development of newer antibody-drug conjugates has demonstrated that some of these lower-expressing tumours may also be susceptible to HER2-directed treatment.

That shift has substantially expanded the potential population that could benefit from HER2-targeted medicines and has encouraged pharmaceutical companies to develop ADCs capable of functioning across a wider range of HER2 expression.

TQB2102 is being developed within this rapidly evolving treatment landscape, and its dual-targeting architecture is intended to differentiate it from existing HER2-directed therapies.

A Strategic Addition to Cipla’s Oncology Portfolio

The transaction is significant for Cipla because oncology is increasingly moving towards treatments defined by molecular targets, antibodies and precision drug-delivery technologies. Licensing an advanced ADC gives the company access to a class of medicines requiring substantially different scientific and regulatory capabilities from traditional small-molecule generics.

The partnership could also eventually improve access to advanced cancer therapies in emerging markets, where cost, regulatory timelines and commercial availability can result in significant gaps between the launch of innovative treatments in major developed markets and their introduction elsewhere.

However, the agreement does not mean that TQB2102 will immediately become available to patients in India. Cipla must first undertake the required clinical and regulatory work, and the medicine will have to demonstrate adequate safety, efficacy and manufacturing quality before receiving any marketing authorisation.

The five emerging markets covered in addition to India and South Africa have not been publicly identified in Cipla’s announcement, and financial terms of the transaction have also not been disclosed.

Bringing Advanced Cancer Drug Development Closer to India

The broader significance of the agreement lies in Cipla’s decision to participate directly in the regional development of a late-stage targeted cancer therapy rather than waiting to introduce a medicine only after its global development is complete.

For now, Rolditamig Deuderuxtecan remains an investigational drug whose early clinical results require confirmation. Nevertheless, Cipla’s agreement with Sino Biopharmaceutical places a major Indian pharmaceutical company directly inside the development pathway of a new-generation bispecific antibody-drug conjugate, reflecting the growing role of Indian companies in bringing sophisticated biological medicines and precision cancer therapies to emerging healthcare markets.

---